On September 28, 2019 ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, reported new preclinical data on ESSA’s lead Investigational New Drug ("IND") candidate at the 2019 American Urological Association ("AUA") Annual Meeting (Press release, ESSA, SEP 28, 2019, View Source [SID1234539899]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In an oral poster presentation titled, "EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer", a deeper preclinical characterization of EPI-7386 was presented. The poster shows that, in preclinical studies, EPI-7386 demonstrates:

Activity in multiple in vitro full length androgen receptor (AR) and AR-V7 splice variant driven cellular models.
Robust antitumor activity as a single agent and in combination with enzalutamide in the VCaP xenograft prostate cancer model.
Antitumor activity in enzalutamide-resistant prostate cancer xenograft models, 22Rv1 and LNCaP95, with no antitumor activity, as expected, in a non-functional androgen receptor PC-3 prostate cancer xenograft model.
Wide therapeutic index as demonstrated by a broad dose response in the VCaP model.
High plasma exposures in animal studies using a new suspension formulation.
Abstract ID:

503P

Abstract Title:

EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for
the treatment of prostate cancer

Presenter:

Ronan Le Moigne, PhD

Date:

Saturday September 28, 2019

Time:

12:00pm CEST

Location:

Hall 4, Fira Gran Via, Barcelona, Spain